Skip to main content
. 2017 Dec 13;57(3):499–507. doi: 10.1093/rheumatology/kex443

Fig. 1.

Fig. 1

Patient disposition at baselinecsDMARD: conventional synthetic disease-modifying anti-rheumatic drug; qw: once weekly; TCZ-SC: subcutaneous tocilizumab.